MAPT and supranuclear palsy, progressive, 1: GABRG2 levels were found to be reduced in iPSC‐derived neurons and brains from MAPT p.R406W carriers, mouse models of tauopathy,57 and in the Mayo Clinic brain RNAseq data22 from patients with the primary tauopathy PSP compared with controls, in both TCX and cerebellum.